Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites (SBIR [R43/R44])

Post Date

July 31st 2009

Application Due Date

November 9th 2009

Funding Opportunity Number

RFA-AI-09-029

CFDA Number(s)

93.856

Funding Instrument Type(s)

Grant

Funding Activity Categories

Health

Eligibility Categories

Small Businesses

Funding

• Estimated Total Funding:

  $3000000

• Award Range:

  $None - $None

Grant Description

Purpose. This Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to conduct translational research leading to development of therapeutic and diagnostic technologies for drug-resistant bacteria and eukaryotic parasites. Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II and Fast-Track applications and runs in parallel with an FOA of identical scientific scope, RFA-AI-09-026, which invites applications under the R01 research project grant mechanism. Funds Available and Anticipated Number of Awards. The estimated amount of funds available for support of 5 projects awarded as a result of this announcement is $3 million in total costs for fiscal year 2010. Future year amounts will depend on annual appropriations.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-09-029.html